Skip to main content

Table 2 Randomized controlled trials of neoadjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma

From: Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Study Histology SCC (%) Treatment n MS (months) 3-year OS (%) P value
Schlag [18] SCC 100 CF 22 7   NS
    Surgery 24 6   
Nygaard and colleagues [14] SCC 100 BC 44 7 3 NS
    Surgery 41 7 9  
Maipang and colleagues [19] SCC 100 BVC 24 17 31 NS
    Surgery 22 17 36  
Law and colleagues [20] SCC 100 CF 74 17 40 NS
    Surgery 73 13 13  
Ancona and colleagues [21] SCC 100 CF 47 25 34a NS
    Surgery 47 24 22a  
Kelsen and colleagues [22] AC/SCC 54 CF 213 15 19a NS
    Surgery 227 16 20a  
Allum and colleagues [23] AC/SCC 31 CF 400 17 43 <0.01
    Surgery 402 13 34  
  1. aFive-year overall survival (OS). AC adenocarcinoma, BC bleomycin + cisplatin, BVC bleomycin + vindesine + cisplatin, CF cisplatin + fluorouracil, MS median survival, NS not significant, SCC squamous cell carcinoma.